Blastic EBV-associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia

0Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication of organ transplantation. Progress has recently been made in the pathological classification of PTLD. However, the clinical course has not been clarified because of the rarity of this disease. We experienced a case of PTLD with a fulminant clinical course. The patient had been under longterm immunosuppressive treatment for aplastic anemia. He received related allogeneic hematopoietic stem cell transplantation. Soon after transplantation, he developed PTLD. According to the guidelines, we reduced immunosuppression. However, the disease course was so fulminant that there was no time for the patient to respond, and he died of multi-organ failure. There may be various clinical types of PTLD, which may include some fulminant cases. In such a case, it is not sufficient to reduce immunosuppression. The patient should be carefully observed and an appropriate individual treatment should be chosen.

Cite

CITATION STYLE

APA

Hotta, M., Nakaya, A., Fujita, S., Satake, A., Nakanishi, T., Azuma, Y., … Nomura, S. (2018). Blastic EBV-associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia. Hematology Reports, 10(2). https://doi.org/10.4081/hr.2018.7527

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free